Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 40, 2016, Pages E5830-E5837

  Shanker, Sreejesh ^a   Czakó, Rita ^a   Sapparapu, Gopal ^b   Alvarado, Gabriela ^b   Viskovska, Maria ^a   Sankaran, Banumathi ^c   Atmar, Robert L ^a   Crowe, James E ^b   Estes, Mary K ^a   Venkataram Prasad, B V ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Antibody neutralization; Crystal structure; HBGA blockade antibody; Norovirus; Viral entry

Indexed keywords

BLOOD GROUP ANTIGEN; CAPSID PROTEIN; EPITOPE; HISTO BLOOD GROUP ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMMUNOGLOBULIN A 512; UNCLASSIFIED DRUG; ANTIGEN; BLOCKING ANTIBODY; IMMUNOGLOBULIN A; VIRAL PROTEIN;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; GENETIC VARIABILITY; GENOTYPE; HEAVY CHAIN; LIGHT CHAIN; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; SERODIAGNOSIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANTIBODIES, BLOCKING; ANTIGENS; BLOOD GROUP ANTIGENS; CRYSTALLOGRAPHY, X-RAY; EPITOPES; GENOTYPE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, MOLECULAR; NEUTRALIZATION TESTS; NOROVIRUS; PROTEIN DOMAINS; VIRAL PROTEINS;

EID: 84989847201     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1609990113     Document Type: Article

References (62)

1. Ahmed SM, et al. (2014) Global prevalence of norovirus in cases of gastroenteritis: A systematic review and meta-analysis. Lancet Infect Dis 14(8):725-730.
2. Patel MM, et al. (2008) Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 14(8):1224-1231.
3. Treanor JJ, et al. (2014) A novel intramuscular bivalent norovirus virus-like particle vaccine candidate-reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis 210(11):1763-1771.
4. Atmar RL, et al. (2011) Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 365(23):2178-2187.
5. Green KY, et al. (2000) Taxonomy of the caliciviruses. J Infect Dis 181(suppl 2):S322-S330.
6. Ramani S, Atmar RL, Estes MK (2014) Epidemiology of human noroviruses and updates on vaccine development. Curr Opin Gastroenterol 30(1):25-33.
7. Lindesmith LC, Donaldson EF, Baric RS (2011) Norovirus GII.4 strain antigenic variation. J Virol 85(1):231-242.
8. Hutson AM, Atmar RL, Graham DY, Estes MK (2002) Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 185(9):1335-1337.
9. Lindesmith L, et al. (2003) Human susceptibility and resistance to Norwalk virus infection. Nat Med 9(5):548-553.
10. Nordgren J, Sharma S, Kambhampati A, Lopman B, Svensson L (2016) Innate Resistance and Susceptibility to Norovirus Infection. PLoS Pathog 12(4):e1005385.
11. Prasad BV, et al. (1999) X-ray crystallographic structure of the Norwalk virus capsid. Science 286(5438):287-290.
12. Singh BK, Leuthold MM, Hansman GS (2015) Human noroviruses' fondness for histoblood group antigens. J Virol 89(4):2024-2040.
13. Shanker S, et al. (2014) Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses. J Virol 88(11):6168-6180.
14. Huang P, et al. (2005) Norovirus and histo-blood group antigens: Demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 79(11):6714-6722.
15. Shanker S, et al. (2011) Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: Implications for epochal evolution. J Virol 85(17):8635-8645.
16. Lindesmith LC, et al. (2008) Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 5(2):e31.
17. Choi JM, Hutson AM, Estes MK, Prasad BV (2008) Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci USA 105(27):9175-9180.
18. Cao S, et al. (2007) Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol 81(11):5949-5957.
19. Tan M, et al. (2008) Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology 379(2):324-334.
20. Hansman GS, et al. (2011) Crystal structures of GII.10 and GII.12 norovirus protruding domains in complex with histo-blood group antigens reveal details for a potential site of vulnerability. J Virol 85(13):6687-6701.
21. Kubota T, et al. (2012) Structural basis for the recognition of Lewis antigens by genogroup I norovirus. J Virol 86(20):11138-11150.
22. Singh BK, et al. (2015) Structural analysis of a feline norovirus protruding domain. Virology 474:181-185.
23. Reeck A, et al. (2010) Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 202(8):1212-1218.
24. Ramani S, et al. (2015) Mucosal and cellular immune responses to Norwalk virus. J Infect Dis 212(3):397-405.
25. Lindesmith LC, et al. (2015) Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: Immunological analyses from a phase I clinical trial. PLoS Med 12(3):e1001807.
26. Chen Z, et al. (2013) Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis. J Virol 87(17):9547-9557.
27. Knoll BM, Lindesmith LC, Yount BL, Baric RS, Marty FM (2016) Resolution of diarrhea in an immunocompromised patient with chronic norovirus gastroenteritis correlates with constitution of specific antibody blockade titer. Infection 44(4):551-554.
28. Lindesmith LC, et al. (2012) Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 8(5):e1002705.
29. Lay MK, et al. (2010) Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology 406(1):1-11.
30. Herbst-Kralovetz MM, et al. (2013) Lack of norovirus replication and histo-blood group antigen expression in 3-dimensional intestinal epithelial cells. Emerg Infect Dis 19(3):431-438.
31. Kwong PD, Mascola JR, Nabel GJ (2011) Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 1(1):a007278.
32. Wei CJ, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329(5995):1060-1064.
33. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS (2008) Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: Implications for vaccine development. Cell Host Microbe 4(3):229-238.
34. Sapparapu G, et al. (2016) Frequent use of the IgA isotype in human B cells encoding potent norovirus-specific monoclonal antibodies that block HBGA binding. PLoS Pathog 12(6):e1005719.
35. Bok K, et al. (2011) Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci USA 108(1):325-330.
36. Lindesmith LC, et al. (2012) Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol 86(2):873-883.
37. Debbink K, Lindesmith LC, Donaldson EF, Baric RS (2012) Norovirus immunity and the great escape. PLoS Pathog 8(10):e1002921.
38. Allen DJ, et al. (2009) Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding. Virol J 6:150.
39. Parra GI, et al. (2012) Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens. J Virol 86(13):7414-7426.
40. Taube S, et al. (2010) High-resolution x-ray structure and functional analysis of the murine norovirus 1 capsid protein protruding domain. J Virol 84(11):5695-5705.
41. Kolawole AO, et al. (2014) Flexibility in surface-exposed loops in a virus capsid mediates escape from antibody neutralization. J Virol 88(8):4543-4557.
42. Wang X, et al. (2013) Atomic model of rabbit hemorrhagic disease virus by cryoelectron microscopy and crystallography. PLoS Pathog 9(1):e1003132.
43. Tsuchiya Y, Mizuguchi K (2016) The diversity of H3 loops determines the antigen-binding tendencies of antibody CDR loops. Protein Sci 25(4):815-825.
44. Shirai H, Kidera A, Nakamura H (1999) H3-rules: Identification of CDR-H3 structures in antibodies. FEBS Lett 455(1-2):188-197.
45. North B, Lehmann A, Dunbrack RL, Jr (2011) A new clustering of antibody CDR loop conformations. J Mol Biol 406(2):228-256.
46. Weitzner BD, Dunbrack RL, Jr, Gray JJ (2015) The origin of CDR H3 structural diversity. Structure 23(2):302-311.
47. Czakó R, et al. (2015) Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clin Vaccine Immunol 22(2):221-228.
48. Lindesmith LC, et al. (2013) Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol 87(5):2803-2813.
49. Payne DC, Parashar UD, Lopman BA (2015) Developments in understanding acquired immunity and innate susceptibility to norovirus and rotavirus gastroenteritis in children. Curr Opin Pediatr 27(1):105-109.
50. Hansman GS, et al. (2012) Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle. J Virol 86(7):3635-3646.
51. Bok K, et al. (2009) Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J Virol 83(22):11890-11901.
52. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS (2010) Viral shape-shifting: Norovirus evasion of the human immune system. Nat Rev Microbiol 8(3):231-241.
53. McLean GR, Nakouzi A, Casadevall A, Green NS (2000) Human and murine immunoglobulin expression vector cassettes. Mol Immunol 37(14):837-845.
54. Aiyegbo MS, et al. (2013) Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore. PLoS One 8(5):e61101.
55. Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG (2011) iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 67(pt 4):271-281.
56. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58(pt 11):1948-1954.
57. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(pt 4):658-674.
58. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50(pt 5):760-763.
59. Sok D, et al. (2014) Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci USA 111(49):17624-17629.
60. Terwilliger TC, et al. (2008) Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr D Biol Crystallogr 64(pt 1):61-69.
61. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(pt 12 pt 1):2126-2132.
62. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8(2):127-134.